Royalty Pharma (RPRX) Accounts Payables (2019 - 2026)

Royalty Pharma has disclosed Accounts Payables across 8 years of filings, most recently posting $35.6 million for Q2 2026.

• In Q2 2026, Accounts Payables rose 75.99% year-over-year to $35.6 million; the TTM figure through Jun 2026 stood at $35.6 million (up 75.99% YoY), while the FY2025 annual figure was $19.4 million, up 45.13% from the prior year.
• Accounts Payables came in at $35.6 million for Q2 2026 at Royalty Pharma, up from $25.5 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $41.4 million in Q3 2025 to a low of $5.8 million in Q2 2023.
• Average Accounts Payables over 5 years is $18.6 million, with a median of $15.6 million recorded in 2022.
• Year-over-year, Accounts Payables tumbled 52.29% in 2023 and jumped 303.1% in 2024.
• Over 5 years, Accounts Payables stood at $7.9 million in 2022, then jumped by 91.82% to $15.2 million in 2023, then slipped by 11.84% to $13.4 million in 2024, then soared by 45.13% to $19.4 million in 2025, then jumped by 83.29% to $35.6 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $35.6 million in Q2 2026, $25.5 million in Q1 2026, and $19.4 million in Q4 2025.